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Clinical overview of epithelial ovarian cancer
Epithelial ovarian cancer (EOC) accounts for the majority 
of ovarian cancer and is the most lethal of all gyneco­
logical  malignancies.  It  was  expected  that  21,550  new 
cases of EOC would be diagnosed in the US in 2009 and 
that  14,600  women  would  die  from  the  disease  [1]. 
Although  ovarian  cancer  accounts  for  only  3%  of  all 
female  cancers,  it  is  the  fifth  most  common  cause  of 
cancer deaths in women. Given that EOC usually pre­
sents  with  non­specific  symptoms,  such  as  bloating  or 
abdominal discomfort, which can all be mistaken for a 
more benign condition, and because there is currently no 
means for early detection, patients with EOC are often 
diagnosed with late­stage disease (International Federa­
tion of Gynecology and Obstetrics (FIGO) stage III or 
IV).  On  initial  diagnosis,  patients  undergo  complete 
surgical debulking (resection whose only goal is to make 
subsequent therapy more effective) followed by combina­
tion chemotherapy usually consisting of carboplatin and 
paclitaxel. Approximately 80% of patients respond to this 
treatment  regimen,  which  has  been  the  standard  for 
more than 10 years [2]. However, 60 to 80% of the res­
pon  ders present with recurrent disease between 6 months 
and  2  years  after  treatment.  Unfortunately,  disease 
recurrence is characterized by chemoresistance, resulting 
in disease progression and death. As a result, the 5­year 
survival  rate  for  patients  diagnosed  with  late­stage 
disease is only 15 to 20% [3].
NF-κB in ovarian cancer initiation and progression
Chronic inflammation has been associated with tumor 
initiation and progression. In the ovary, carcinogenesis 
has  been  linked  to  inflammatory  processes,  such  as 
repeated ovulation, endometriosis and pelvic infections 
[4,5].  The  molecular  link  between  inflammation  and 
cancer is nuclear factor κ light chain enhancer of activated 
B cells (NF­κB) [6]. The NF­κB family of proteins, which 
has five members (Table 1), controls several key processes 
that are required for tumor develop  ment and progression, 
such  as:  activation  of  anti­apoptotic  genes  and  genes 
involved in the progression of cell cycle [7,8]; secretion of 
factors such as tumor necrosis factor (TNF) α and inter­
leukin (IL)­6, which enhances cell growth [6]; promo  tion 
of  a  pro­angiogenic  environment  through  enhanced 
production  of  IL­8  and  vascular  endothelial  growth 
factor [9]; and creation of a microenvironment that may 
prevent immune surveillance [10] (Figure 1).
A  correlation  between  NF­κB  activation  and  EOC 
clinical  profile  has  been  described.  Guo  et  al.  [11] 
demonstrated that the expression of NF­κB p65 in EOC 
tumors  is  mainly  nuclear  and  that  the  levels  correlate 
with poor differentiation and late FIGO stage. Moreover, 
they showed that patients who were positive for NF­κB 
p65 subunit staining had lower cumulative survival rates 
and lower median survival (20% and 24 months, respec­
tively)  than  patients  that  were  negative  (46.2%  and 
39 months, respectively). The correlation between NF­κB 
activation status (that is, levels of NF­κB p65 and RelB) 
and poor clinical outcome in EOC patients was corro  bor­
ated  in  more  recent  studies  by  two  other  independent 
groups [12,13].
In addition to these correlation studies [11­13], the in 
vitro  activation  or  specific  inhibition  of  the  NF­κB 
pathway using either small­molecule inhibitors or short 
interfering RNA (siRNA) was recently shown to affect the 
growth behavior of EOC cells. Using the ligand TNF­like 
weak inducer of apoptosis (TWEAK) to activate NF­κB 
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© 2010 BioMed Central Ltdin  the  highly  metastatic  human  EOC  cell  line  HO­
8910PM, Dai et al. [14] showed that although TWEAK­
induced  nuclear  translocation  of  NF­κB  p65  does  not 
enhance cell growth, treatment with TWEAK for 6 hours 
can  significantly  enhance  adhesion  and  promote  the 
migration and invasion capacity of these cells [14]. These 
effects  were  inhibited  when  cells  were  treated  with 
TWEAK in the presence of the NF­κB inhibitor pyrro­
lidine dithiocarbamate.
In  another  study,  which  showed  that  microRNA­9 
(miR­9) could control the levels of NF­κB1, the authors 
[15] showed that a decrease in NF­κB1 levels, as a result 
of overexpressing miR­9 or by using the siRNA expres­
sion  vector  pSilencer/si­NF­κB1,  is  associated  with  a 
reduction  in  cell  growth  and  colony  formation  by  the 
human EOC line ES­2.
In a more recent study using several EOC cell lines, 
Hernandez et al. [16] showed that inhibition of the NF­
κB  pathway  through  specific  inhibition  of  inhibitor  of 
NF­κB kinase β (IKKβ) can decrease the percentage of 
viable  CAOV3,  IGROV1  and  A2780  cells.  In  addition, 
they showed that blocking IKKβ activity through either 
small­molecule  inhibition  or  siRNA  can  inhibit 
anchorage­independent growth and the capacity of the 
cells  to  invade  through  a  basement  membrane.  More 
importantly, the authors [16] identified the network of 
genes controlled by the IKKβ­NF­κB pathway in CAOV3 
cells.  Using  the  highly  specific  IKKβ  small­molecule 
inhibitor  ML120b  or  IKKβ  siRNA  to  decrease  IKKβ 
expression,  gene  expression  microarray  results  showed 
that the IKKβ­NF­κB pathway controls genes associated 
with  EOC  cell  proliferation,  adhesion,  invasion, 
angiogenesis  and  the  creation  of  a  pro­inflammatory 
micro  environment.
NF-κB signaling and ovarian cancer stem cells
Our group has identified a subpopulation of EOC cells 
that  is  responsive  to  the  pathway  involving  Toll­like 
receptor 4 (TLR4) and NF­κB [17]. Treatment with the 
chemotherapy agent paclitaxel, which is a known TLR4 
ligand,  induced  NF­κB  activation,  leading  to  enhanced 
cell proliferation. NF­κB is constitutively active in these 
cells,  resulting  in  constitutive  secretion  of  pro­inflam­
matory  cytokines  [17],  and  this  is  brought  about  by 
consti  tutive IKKβ activity [18]. These cells also express 
the  cancer  stem  cell  marker  CD44  and  are  in  fact  the 
ovarian cancer stem cells (OCSCs) [19].
The CD44+ OCSCs are resistant to chemotherapeutic 
agents,  and  this  resistance  is  partly  regulated  by  the 
NF­κB pathway [19]. In our most recent study [20], we 
showed  that  the  NF­κB  inhibitor  Eriocalyxin  B  can 
sensitize these cells to TNFα­ and Fas­mediated apop­
tosis.  The  CD44+  OCSCs  can  also  serve  as  tumor 
vascular progenitors in vitro and in vivo, an effect also 
regulated by the NF­κB pathway [21].
Conclusions
Research in the past 5 years has unraveled the multiple 
mechanisms  that  enable  NF­κB  to  support  ovarian 
carcinogenesis, including that this pathway confers some 
of the properties of OCSCs. These findings highlight the 
clinical  potential  for  NF­κB  inhibitors  to  prevent 
recurrence and improve survival in EOC patients. The 
fact that the main effectors of this pathway significantly 
correlate with disease activity suggests the feasibility of 
choosing  patients  that  may  benefit  from  targeting  this 
molecular pathway.
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Figure 1. The NF-κB pathway. In unstimulated cells, the NF-κB 
subunits p65 and p50 are sequestered in the cytoplasm by IκB. 
Ligand binding to receptors (such as TNFα and TLR4) leads to the 
activation of the IKK complex, which then phosphorylates IκB. 
Phosphorylated IκB is then ubiquitinated and degraded by the 
proteasome system, leading to the release of p65 and p50. The 
heterodimer then translocates to the nucleus and initiates the 
expression of genes that regulate proliferation, cell death, invasion, 
migration and immune regulation. This is the canonical pathway; 
there is also a non-canonical pathway involving other NF-κB family 
members. Most of the studies on EOC have looked at the members 
of the canonical pathway.
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Table 1. Members of the NF-kB family of proteins
Member  Other names
NFκB1  NFκB, p105, p50, p50/p105
NFκB2  p52
NFκB3  RelA, p65
RelB 
c-Rel 
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